Cubicin (daptomycin) patents declared invalid by Supreme Court- Cubist Pharma/Merck Inc.
The U.S. Supreme Court has opened the way for Hospira Inc. to introduce a generic version of Cubicin (daptomycin).The Supreme Court did not disturb a November decision by the U.S. Court of Appeals for the Federal Circuit upholding a lower court ruling that invalidated four of five patents held by Cubist Pharma (which is owned by Merck Inc.), which were challenged by Hospira ( which is owned by Pfizer). The appeals court decided that four of the patents, expiring in 2019 and 2020, were invalid, and that one, expiring in June of 2016, was valid, which has the effect that Hospira can proceed with a generic version of the drug.
Related news and insights
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.
Mirati Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for MRTX 849 (adagrasib) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.